Etomoxir ( (R)- (+)-Etomoxir，乙莫克舍) - 仅供科研 - MCE
Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
Etomoxir - Wikipedia
Etomoxir, or rac-Ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate, in form of the dextrorotatory (R)-(+)- enantiomer, is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1; EC 2.3.1.21) on the inner face of the outer mitochondrial membrane. [2]
The CPT1a inhibitor, etomoxir induces severe oxidative stress …
2018年4月19日 · Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a).
Etomoxir sodium salt | 乙莫克舍（钠盐） | CPT 抑制剂 | 现货供应 …
Etomoxir已进行过临床I/Ⅱ期研究，用于治疗中度充血性心力衰竭。 目前试验被终止，因为有4名患者（226名试验人员）在用药后引起了高水平的肝脏转氨酶，这一副作用的风险使这一药物潜在的治疗效果被否决 [3] 。
The CPT1a inhibitor, etomoxir induces severe oxidative stress at ...
Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). We used this compound to evaluate the role of fatty acid oxidation in rapidly proliferating T cells following costimulation through the CD28 receptor.
Etomoxir - an overview | ScienceDirect Topics
Etomoxir is an inhibitor of carnitine palmitoyltransferase I initially developed as an antidiabetic agent. There is now increasing interest in the role of energy substrate switching in heart failure, and this drug (along with pyruvate supplementation) are in early …
Etomoxir - an overview | ScienceDirect Topics
Etomoxir is an irreversible CPT1-specific inhibitor preventing the transport from fatty acids into the mitochondrial matrix for further metabolization. The compound has been developed in the 1980s and reached Phase II clinical trials such as the ERGO-trial [49] , which however had to be terminated prematurely because of elevated transaminase ...
乙莫克舍(Etomoxir) - 药物靶点：CPT1B_在研适应症：胶质母细胞 …
据此，研究团队利用 Etomoxir 等 FAO 抑制剂或通过构建 LTi 细胞 FAO 限速酶 Cpt1 的条件性敲除小鼠，均有效恢复了 PD-1 信号缺失 LTi 中的 IL-22 表达。 单细胞测序分析LTi细胞活化过程的代谢重塑 总而言之，该研究揭示了 PD-1 信号调控肠道 LTi 细胞活化过程中的代谢重 ...
Etomoxir | 乙莫克舍 | CPT | Antioxidant | TargetMol
Etomoxir 是肉碱棕榈酰转移酶 1a （CPT-1a） 抑制剂，通过抑制 CPT-1a 来抑制脂肪酸氧化，且抑制人、大鼠和豚鼠中棕榈酸酯的氧化。 Etomoxir 对腺嘌呤核苷酸转位酶有抑制作用，可通过破坏CoA稳态来抑制巨噬细胞极化。
- 评论数: 10
Etomoxir: a new approach to treatment of chronic heart failure
2000年11月11日 · Etomoxir is an oxirane carboxylic acid derivative that is an inhibitor (Ki of 8 μM) of carnitine palmitoyltransferse-I (CPT-I). 1 CPT-I is a mitochondrial enzyme that plays a key role in the transport of long-chain acyl-CoA compounds into the mitochondria, so etomoxir inhibits fatty-acid metabolism but promotes that of glucose. 2,3 Etomoxir ...